Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
RAUltragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ Global Select · Currency in USD
$15.97 ▲ +0.32 (+2.01%)
At close: Oct 26, 3:37 PM ET. Market closed.

Summary

Previous Close
$15.65
Open
$15.77
Day's Range
$15.60 – $16.20
52 Week Range
$12.73 – $39.89
Volume
1,866,641
Avg. Volume
3,762,622
Market Cap
$1.57B
Beta (5Y Monthly)
0.32
PE Ratio (TTM)
--
EPS (TTM)
-$5.75
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$25.46

Profile: Ultragenyx Pharmaceutical Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,371
CEO
Emil D. Kakkis

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$1.10 · Revenue est. $182.49M
DateEst.Actual
Aug 4, 2026-$1.22-$0.90Beat
May 5, 2026-$1.49-$1.84Miss
Feb 12, 2026-$1.20-$1.29Miss
Nov 4, 2025-$1.23-$1.81Miss
Aug 5, 2025-$1.27-$1.17Beat
May 6, 2025-$1.54-$1.57Miss

Analyst view

Consensus price target
$25.46 ▲ +59.5%
Range $16.00 – $39.00
Rating: Buy
Buy 65% · Hold 32% · Sell 3%

Get free alerts on RARE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.